» Articles » PMID: 29186468

Analysis of Memory B-Cell Responses Reveals Suboptimal Dosing Schedule of a Licensed Vaccine

Overview
Journal J Infect Dis
Date 2017 Nov 30
PMID 29186468
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Current guidance recommends that adolescents receive a 2-dose human papillomavirus (HPV) vaccine, whereas young adults and immunocompromised persons receive 3 doses. We examined secondary responses of vaccine-elicited memory B cells (Bmem) in naive women receiving 3 doses of the quadrivalent HPV vaccine to understand the quality of B-cell memory generated by this highly effective vaccine. Unexpectedly, we observed a lower Bmem response rate and magnitude of Bmem responses to the third dose than to a booster dose administered at month 24. Moreover, high titers of antigen-specific serum antibody at vaccination inversely correlated with Bmem responses. As the purpose of additional doses/boosters is to stimulate Bmem to rapidly boost antibody levels, these results indicate the timing of the third dose is suboptimal and lend support to a 2-dose HPV vaccine for young adults. Our findings also indicate more broadly that multidose vaccine schedules should be rationally determined on the basis of Bmem responses.

Citing Articles

ULACNet-301, OPTIMO protocol: optimizing HPV vaccination regimen for cancer prevention in children and adolescents living with HIV.

Pinto-Santini D, Jalil E, Fernandes G, Hilaire G, Kolevic L, Cabello R BMC Cancer. 2025; 25(1):151.

PMID: 39871186 PMC: 11771066. DOI: 10.1186/s12885-025-13551-z.


Immunogenicity of 2 or 3 Doses of 9vHPV Vaccine in U.S. Female Individuals 15 to 26 Years of Age.

Berenson A, Panicker G, Unger E, Rupp R, Kuo Y NEJM Evid. 2024; 3(2):EVIDoa2300194.

PMID: 38320488 PMC: 11771182. DOI: 10.1056/EVIDoa2300194.


B Cell Responses upon Human Papillomavirus (HPV) Infection and Vaccination.

Prabhu P, Carter J, Galloway D Vaccines (Basel). 2022; 10(6).

PMID: 35746445 PMC: 9229470. DOI: 10.3390/vaccines10060837.


Generation of a cost-effective cell line for support of high-throughput isolation of primary human B cells and monoclonal neutralizing antibodies.

Whaley R, Ameny S, Arkatkar T, Seese A, Wall A, Khan I J Immunol Methods. 2020; 488:112901.

PMID: 33069767 PMC: 7560121. DOI: 10.1016/j.jim.2020.112901.


Rationalizing the HPV vaccination schedule: A long road to a worthwhile destination.

Brotherton J Papillomavirus Res. 2019; 8:100190.

PMID: 31759174 PMC: 6889720. DOI: 10.1016/j.pvr.2019.100190.


References
1.
Amanna I, Carlson N, Slifka M . Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007; 357(19):1903-15. DOI: 10.1056/NEJMoa066092. View

2.
de Sanjose S, Quint W, Alemany L, Geraets D, Klaustermeier J, Lloveras B . Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11):1048-56. DOI: 10.1016/S1470-2045(10)70230-8. View

3.
Buck C, Pastrana D, Lowy D, Schiller J . Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med. 2005; 119:445-62. DOI: 10.1385/1-59259-982-6:445. View

4.
Victora G, Nussenzweig M . Germinal centers. Annu Rev Immunol. 2012; 30:429-57. DOI: 10.1146/annurev-immunol-020711-075032. View

5.
Smolen K, Gelinas L, Franzen L, Dobson S, Dawar M, Ogilvie G . Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine. 2012; 30(24):3572-9. DOI: 10.1016/j.vaccine.2012.03.051. View